MTN 030/IPM 041
Status:Completed
Phase:I
Principal Investigator(s):
Objective:MTN-030 is a Phase I study that seeks to determine whether a woman’s use of a vaginal ring containing both the antiretroviral (ARV) drug dapivirine and the contraceptive drug Levonorgestrel is a safe and effective method for protecting against both unwanted pregnancy and HIV infection. The study will enroll women at two U.S. sites.
*Study is currently in the data analysis phase*
Prevention Option(s):MPTs
Study Design:Double-blind, Randomized
Arms and Assigned Interventions
DescriptionA silicone elastomer vaginal matrix ring containing 200 mg of dapivirine alone
Mode of DeliveryRing
ARMsExperimental
DescriptionA silicone elastomer vaginal matrix ring 200 mg of dapivirine and 320 mg of levonorgestrel.
Mode of Delivery
ARMsExperimental
Official Code:
NCT02855346
Trial Sponsors:
IPM
Start Date
End Date
June 14, 2017
December 12, 2017
Enrollment:24
Age range:
18 Years ↔
45 Years
Population:Cisgender Women